| Patient | Mildred Ella Didrikson Zaharias |
|---|---|
| Date of birth | 1984-06-26 |
| Identifiers | MRN HR-ML038-SYN; SSN (made up) 000-38-4471 |
| Document date | 2026-06-29 |
| Author | Rosalind Vasquez-Thornbury, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Restaging after four doses of dostarlimab, and tiredness with cold hands. [S]
Ms. Didrikson Zaharias comes on the day of her fifth dose, after restaging MRI and sigmoidoscopy last week. The cold she had in early June cleared within a week and she had cycle 4 on time. Over the last month she has become tired again, with cold hands on the course, dry skin and slightly heavier legs; her weight is up 0.8 kg. At the sick visit four weeks ago the TSH was 5.8 mIU/L with a normal free T4. Her bowel movements are normal, with no bleeding, and she has had no diarrhea, rash, cough or breathlessness. Sex is comfortable again. She is playing 18 holes and has entered a club competition next month. [S]
| Element | Detail |
|---|---|
| Treatment | Dostarlimab cycles 1 to 4 on schedule; cycle 5 today |
| Restaging | MRI: near-complete response; sigmoidoscopy: flat scar with a 5 mm shallow ulcer |
| New symptoms | Tiredness, cold hands, dry skin for a month |
| Sport | Playing 18 holes; entered a club competition |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for a month; weight 63.8 kg, up 0.8 kg |
| Integumentary | Positive | Dry skin; no rash |
| Endocrine | Positive | Cold hands; no thirst or headache |
| Gastrointestinal | Negative | Normal bowel movements; no bleeding or diarrhea; mild constipation |
| Respiratory | Negative | Cough gone; no breathlessness |
| Psychiatric | Negative | Pleased with the scans; PHQ-9 3; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning | One tablet every other morning | Oral route | 2026-03-30 | active | S |
| Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) | 500 mg every 3 weeks for nine doses | Intravenous route | 2026-04-06 to 2026-09-21 | completed | S |
| Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron | One tablet each morning | Oral route | 2026-06-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-29 | Body height | 168 | cm | S |
| 2026-06-29 | Body weight | 63.8 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 60 | /min | S |
| 2026-06-29 | Respiratory rate | 14 | /min | S |
| 2026-06-29 | Body temperature | 36.4 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-29 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-29 | Leukocytes [#/volume] in Blood by Automated count | 6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-29 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-29 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.75 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 89 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-35 U/L | Normal | S |
| 2026-06-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-35 U/L | Normal | S |
| 2026-06-29 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 70 | U/L | 35-104 U/L | Normal | S |
| 2026-06-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-06-29 | Albumin [Mass/volume] in Serum or Plasma | 4.4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-29 | Thyrotropin [Units/volume] in Serum or Plasma | 12.6 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 2026-06-29 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.6 | ng/dL | 0.8-1.8 ng/dL | Low | S |
| 2026-06-29 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 2.1 | ng/mL | Up to 3.0 ng/mL in non-smokers | Normal | S |
| 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 63.8 kg; blood pressure 114/72, pulse 60; temperature 36.4 °C |
| Neck | Thyroid not enlarged or tender |
| Skin | Dry skin on the shins; no rash |
| Neurological | Ankle reflexes with slightly slow relaxation |
| Rectal | With her agreement and a chaperone: smooth, with a small firm irregularity at about 4 cm; no mass; no blood |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week | resolved | confirmed | K62.5 | S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season. |
| Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly | active | confirmed | C20 | S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md. |
| Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
| Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continued | active | confirmed | E03.2 | S — Synthetic common immune-related adverse event of PD-1 blockade. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Restaging pelvic MRI and flexible sigmoidoscopy | About every three months during treatment | Up to date | Last week: near-complete response on MRI; flat scar with a 5 mm shallow ulcer on sigmoidoscopy |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Smooth, with a small firm irregularity at about 4 cm; no mass |
| Laboratory | CEA | At diagnosis, at each restaging, then every three to six months for two years | Completed today | 2.1 ng/mL, normal |
| Laboratory | Blood count | Before each dose of dostarlimab and at each visit; about four weeks after oral iron starts | Completed today | Hemoglobin 13.0 g/dL, white cells 6.0, platelets 268 |
| Laboratory | Kidney and liver function and glucose | Before each dose of PD-1 blockade | Completed today | Sodium 140, potassium 4.2 mmol/L; creatinine 0.75 mg/dL, eGFR 102; glucose 89 mg/dL; ALT 20, AST 22, alkaline phosphatase 70 U/L; bilirubin 0.5 mg/dL; albumin 4.4 g/dL |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | TSH 12.6 mIU/L, free T4 0.6 ng/dL: hypothyroidism; levothyroxine started; TSH checks four and five weeks apart since the last visit |
| Examination | Immune-related adverse event review (diarrhea, rash, cough, breathlessness, fatigue, endocrine symptoms) | Before each dose | Completed today | Hypothyroidism, grade 2; no colitis, rash, pneumonitis or hepatitis |
| Laboratory | Ferritin after oral iron | About three months after starting | Deferred | Missed: the ferritin due about three months after oral iron began was not added to the restaging blood tests. No harm is expected, because the bleeding has stopped and the hemoglobin is normal; corrective action: ferritin added to the final restaging blood tests, and iron continued until then |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 3; item 9 scored 0 |
| Self-management | Sexual health and body image | Through treatment | Completed today | Sex comfortable again since the bleeding stopped |
| Self-management | Physical activity and sport | Each visit | Completed today | Playing 18 holes; entered a club competition |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)
Follow-up: Dostarlimab cycles 6 to 9 as booked; TSH and free T4 in six weeks; final restaging after cycle 9; preventive visit due. Next scheduled visit 2026-08-10: periodic adult preventive visit during immunotherapy. [S]